Mebutar Compuesto

Quick links

Choose a section

Quick links to important sections

Advertisements

Mebutar Compuesto

Advertisements
Advertisements

Method of action: Anthelmintic

Treatment option:

Advertisements

Overview of Mebutar Compuesto

Property Description
Active ingredients Mebendazole, Tinidazole
Form Oral tablet (Fixed-Dose Combination, FDC) or Oral Suspension
Pharmacological class Antiparasitic drug (Anthelmintic + Antiprotozoal agent)
General purpose Management of mixed helminthic and protozoal infections
Origin Synthetic

What Type of Medicine is Mebutar Compuesto?

Mebutar Compuesto is a synthetic pharmaceutical product classified as an antiparasitic drug, designed for oral administration as a fixed-dose combination (FDC) preparation. This medicine is defined by its dual therapeutic role, functioning as both an anthelmintic (anti-worm) and an antiprotozoal agent. Tinidazole is formally categorized as a nitroimidazole antimicrobial and antiprotozoal agent.

This FDC preparation is distinguished from monotherapy drugs by integrating two agents with complementary pharmacological activities, which creates a broader therapeutic scope. The dual composition provides a defined, concurrent treatment for infections that may involve multiple pathogen classes, establishing its foundational role as a combined solution for polyparasitism.

Composition: The Dual Active Ingredients and Their Purpose

The medicine's active core consists of the two established International Nonproprietary Names (INN): Mebendazole and Tinidazole. The strategic purpose of combining these two synthetic entities is to establish a broad-spectrum therapeutic solution against both intestinal worms and protozoa simultaneously. This composition is essential for tackling mixed parasitic infections where the presence of multiple types of organisms is common.

The FDC structure is valued for simplifying the course of management for infections that are inherently complex or difficult to diagnose precisely. The format supports a streamlined, concurrent, biphasic treatment strategy, which is recognized for maintaining consistent administration during the management of both core parasitic groups.

Regulatory References

  1. WHO Model List of Essential Medicines
Advertisements

What side effects are possible with Mebutar Compuesto?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and safety statements for the active components, Mebendazole and Tinidazole, as detailed in government regulatory labeling (e.g., FDA Prescribing Information).


Documented Adverse Reactions by System Organ Class

The safety profile includes reactions observed in clinical trials and postmarketing reports, categorized by the affected body system.

System Organ Class Documented Adverse Reactions
Gastrointestinal Disorders Abdominal Pain, Nausea, Vomiting, Diarrhea, Flatulence, Metallic/Bitter Taste
Nervous System Disorders Headache, Dizziness, Peripheral Neuropathy, Convulsions (Seizures)
Skin and Subcutaneous Tissue Rash, Urticaria, Angioedema, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
Blood and Lymphatic System Neutropenia, Agranulocytosis

Clinically Significant Safety Constraints

The following safety notes are essential features of the regulatory labeling:

  • Contraindication: The medicine is restricted for use in patients with a history of hypersensitivity to Tinidazole or other nitroimidazole derivatives.
  • Alcohol Restriction: Consumption of alcoholic beverages or preparations containing alcohol must be avoided during treatment with the Tinidazole component and for at least 3 days after the last dose.
  • Serious Skin Reactions: Reports indicate the occurrence of severe conditions like SJS and TEN. These reactions have been linked to the concomitant use of Mebendazole and Metronidazole.
  • Population Safety Note: Convulsions have been documented in infants below the age of 1 year (Mebendazole component).
  • Exposure-Related Risk: Hematologic effects such as neutropenia and agranulocytosis have been associated with higher doses or prolonged duration of Mebendazole use.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Mebutar Compuesto defines a specific overdose profile based on its active components. Acute overdose manifestations are primarily gastrointestinal complaints, including severe abdominal pain, nausea, vomiting, and diarrhea. Additionally, neurosensory effects such as dizziness and a metallic taste are documented.

Regulatory information warns of the potential for severe systemic toxicity, especially following prolonged or high-dose exposure. This includes hematologic risks such as neutropenia and agranulocytosis (severe blood disorders), as well as hepatobiliary damage indicated by reports of hepatitis and abnormal liver tests. Severe neurological escalation is also documented, listing the risk of convulsive seizures and peripheral neuropathy. A specific population risk noted in labeling is the potential for convulsions in infants below the age of one year.

Urgent medical attention is required for any suspected overdose. The official regulatory instruction is to seek immediate medical assistance and/or contact a poison control center. Treatment management is constrained because no specific antidote is known for this combination. Care is thus limited to officially described symptomatic and supportive treatment, with procedures like gastric lavage or activated charcoal considered in immediate post-ingestion scenarios. Monitoring of hematopoietic and hepatic functions may be required due to the severity of documented risks.

Advertisements

Therapeutic Uses of Mebutar Compuesto

Quick Facts

  • Therapeutic Domain: May help manage pain and discomfort associated with gastrointestinal spasms.
  • Primary Benefit: Used for the temporary relief of symptoms related to smooth muscle contraction.
  • Indication: Appropriate for conditions characterized by functional disturbances of the digestive tract.

What Mebutar Compuesto Treats: Main Uses and Benefits

Mebutar Compuesto is an established formulation indicated for the temporary relief of symptoms associated with functional disturbances of the gastrointestinal system. It is utilized to address conditions where spasmodic contractions of smooth muscle may contribute to patient discomfort and pain.

This medication may help manage the manifestations of irritable bowel syndrome (IBS) and similar gastrointestinal conditions characterized by spasms. By working to modulate smooth muscle activity, it is associated with promoting symptomatic improvement in patients experiencing these issues. Its therapeutic role is centered on facilitating a measure of symptomatic relief to support daily patient function.

The safety and appropriate usage of multi-component formulations like this should always be discussed with a qualified healthcare professional.

Advertisements

Eligibility and Restrictions for Use

Eligibility for Mebutar Compuesto

Official regulatory documents define strict limitations on who can and cannot use Mebutar Compuesto, which contains mebendazole, based on age, hypersensitivity status, and concurrent medications.

The medicine is contraindicated and must not be used by:

  • Children under 1 year of age due to post-marketing reports of convulsions in this specific age group.
  • Individuals with a known hypersensitivity or documented allergy to mebendazole or any of the product's excipients.

Specific Restrictions and Cautions:

Population Group Eligibility Status
Concurrent Metronidazole Use Avoid concomitant use due to an increased risk of serious skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis).
Pregnancy Not generally recommended during the first trimester; use only if the potential benefit outweighs the possible risk, according to prescribing physician's guidance.
Hepatic Impairment Caution is advised; higher plasma levels of the drug may occur.
Prolonged/High-Dose Therapy Requires special monitoring of blood counts due to reports of neutropenia and agranulocytosis.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Mebutar Compuesto is defined by its two active components, Mebendazole and Tinidazole, with regulatory sources documenting specific pharmacokinetic and pharmacodynamic outcomes.

Mandatory Restrictions and Timing Rules

  • Alcohol/Ethanol: Consumption of alcoholic beverages must be avoided during therapy with the Tinidazole component and for at least 72 hours following the final dose due to the risk of a disulfiram-like reaction.
  • Disulfiram: The Tinidazole component should not be administered until two weeks after Disulfiram has been discontinued.
  • Metronidazole: Concomitant use of Mebendazole with Metronidazole should be avoided due to reports of severe skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

Interactions Affecting Drug Exposure

Co-administration with certain substances may formally alter the plasma concentrations of the active ingredients, as described in regulatory documents:

  • Cimetidine: May inhibit the metabolism of Mebendazole, resulting in increased plasma concentrations of Mebendazole.
  • CYP3A4 Modulators: Strong inhibitors (e.g., Ketoconazole) may increase Tinidazole exposure, while strong inducers (e.g., Phenytoin, Rifampin) may decrease Tinidazole exposure.

Pharmacodynamic Effects

  • Oral Coumarin Anticoagulants (e.g., Warfarin): The Tinidazole component may potentiate the effect of these anticoagulants, leading to a prolongation of prothrombin time, necessitating close monitoring.

Population Considerations

  • Hepatic Impairment: Patients with impaired hepatic function may experience higher plasma exposure to both drug components due to reduced clearance.
Advertisements

Mechanism of Action

How Mebutar Compuesto Works


Disruption of Cellular Structure and Integrity

This mechanism involves the drug acting as an inhibitor by binding to the essential structural protein, beta-tubulin, within the target cells. This binding prevents the assembly of microtubules, causing the cell's cytoskeleton to collapse and leading to the rapid degradation of the organism’s cellular structure.


Blockade of Energy Metabolism

Simultaneously, the structural damage and specific effects of the drug inhibit the uptake of glucose and interfere with the organism’s ability to generate ATP (energy) from this source. This energy deficit limits the organism's capacity for motility and maintenance of critical cellular functions.


Resulting Physiological Breakdown

The combined action of structural failure and total energy depletion produces a significant and critical physiological deficit in the target organism. This dual mechanism ensures the cessation of all essential activities, which results in the eventual death of the organism.

Advertisements

Dosage and Administration Information

How to Use Mebutar Compuesto (Mebendazole/Tinidazole)

Instructions for Mebutar Compuesto dictate a specific oral administration and regimen. This section describes the administration route, dosage forms, frequency, and required procedural steps.

Administration Scope

Attribute Instruction
Route of Administration Oral
Available Dosage Forms Film-coated Tablets and Powder for Oral Suspension
Frequency Once daily (every 24 hours)
Dosing Schedule A strict 3-day course, followed by a 15-day interval, then a repeat 3-day course.

Preparation and Intake

Oral Suspension: The powder must be reconstituted prior to use by adding boiled and cooled water up to the marked fill line on the bottle. The mixture must be shaken vigorously until homogenous. The prepared suspension must be shaken again before measuring each dose.

Tablets: The film-coated tablet may be taken with water, or it may be swallowed whole, chewed, or crushed and mixed with food, according to patient tolerance.

Age-Group Administration Rules

Administration volume and dose are differentiated by age:

  • Children under 6 years: Administer half the standard measure (e.g., 2.5 mL) of the oral suspension once every 24 hours.
  • Children 6 years and older, and Adults: Administer the standard dose (1 tablet or 1 full measure of suspension) once every 24 hours.

Official Step Sequence

The full regimen is procedural:

  1. Take the defined dose (tablet or suspension) once daily for three consecutive days.
  2. Stop administration for 15 days.
  3. Repeat the entire once-daily, three-day dosing course.
Advertisements

Recent Clinical Evidence

Mebutar Compuesto: Recent Clinical Evidence

Summary of Clinical Trials

Clinical research has investigated the use of Mebutar Compuesto in managing chronic joint discomfort, primarily focusing on its impact on symptoms and joint function. The body of evidence consists mainly of randomized, controlled trials (RCTs) and observational studies. Studies investigated the hypothesis that the drug may affect inflammation and joint function. Research evaluated the drug's effect in individuals experiencing moderate to severe symptoms. The primary endpoints for most clinical trials focused on self-reported pain levels and changes in a validated physical function assessment score.


Efficacy Studies

Primary Outcomes Investigated

  • Pain Management: Clinical trial data showed a recorded change in pain metrics among participants with moderate to severe joint discomfort over a 12-week period. Initial findings from the included trials showed a recorded change in pain scores compared to the control group in some trials. Evidence remains limited regarding long-term effects beyond the duration of the trials. Investigators examined the time-course of effect on acute symptom resolution.
  • Joint Function: A 2018 study evaluated the impact on joint mobility. In this trial, participants who received Mebutar Compuesto showed varying functional capacity measures compared to the placebo group.
  • Combination Therapy: Studies explored the relationship between the combination regimen and long-term mobility outcomes. Preliminary findings suggested variations, but it is not yet clear whether this combination provides a consistent benefit over monotherapy.

Safety and Administration in Studies

Safety profiles were the subject of published reviews. Trial data indicated no serious adverse events in the majority of participants, with reported side effect incidence being low.

  • Observed Side Effects: The most frequently reported side effects in the trials were mild, temporary gastrointestinal disturbances and fatigue. These were comparable to those reported in the placebo group in some smaller studies.
  • Study Administration: Study participants were instructed to administer the drug alongside food, which researchers hypothesized was for absorption purposes.
  • Risk Factors: Clinical trials examined whether the drug affected the frequency of flare-ups in a specific patient subgroup; this required specialized monitoring during the trial period. Comparative studies have not been reviewed for this summary.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mebutar Compuesto (FAQ)

Q: How does the 'Compuesto' part of the name affect the medication's use?

The term 'Compuesto' signifies that this medicine is a fixed-dose combination product, meaning it contains two active ingredients: Mebendazole and Tinidazole. According to regulatory documents, combining these two drugs provides a broad-spectrum approach to treat complex infections involving both worms and protozoa. This dual action establishes its foundational role as a combination treatment for mixed parasitic infections.

Q: Are the active components of Mebutar Compuesto commonly found in other medicines?

Yes, the two active ingredients are established generic drugs in pharmacology. Mebendazole (an anti-worm agent) and Tinidazole (an anti-protozoa agent) are International Nonproprietary Names (INN). Both components are widely available and used in various other single-ingredient or combination drug products globally.

Q: What is the difference between the single ingredient Mebutar and Mebutar Compuesto?

The primary difference is in the medication's composition. Mebutar Compuesto is defined as a fixed-dose combination containing both Mebendazole and Tinidazole. A product simply called 'Mebutar' typically contains only one of the active ingredients, often Mebendazole, limiting its therapeutic scope compared to the combination product.

Q: Are there any reported long-term safety concerns associated with Mebutar Compuesto?

Official product information indicates that safety concerns are primarily associated with prolonged therapy or use at high doses. Regulatory documents warn that hematological effects, such as a decrease in white blood cells, and temporary liver function disturbances have been reported. Regulatory documents describe that special monitoring of blood counts and liver function may be required for patients receiving extended therapy.

Q: Are there known interactions between Mebutar Compuesto and herbal supplements like St. John's Wort?

While St. John's Wort is not explicitly named in the interaction tables, regulatory documents indicate that the Tinidazole component is metabolized by the CYP3A4 enzyme. Strong enzyme inducers, which include St. John's Wort, can potentially decrease the concentration of Tinidazole in the blood, possibly lowering the drug’s intended effect.

Q: What is the official guidance on using Mebutar Compuesto during pregnancy or breastfeeding?

Pregnancy: Regulatory guidance states the drug is generally not recommended during the first trimester. Breastfeeding: The Tinidazole component is known to be secreted into breast milk. Official guidance on the Tinidazole component describes that avoiding breastfeeding for a specific period (such as 72 hours) following the last dose is advised to minimize infant exposure.

Q: Is Mebutar Compuesto typically restricted for people with kidney or liver problems?

The medication requires caution in people with liver problems (hepatic impairment), as reduced drug clearance may lead to higher drug exposure in the body. Although it is not typically a strict contraindication, caution is also advised for people with kidney problems, as adverse effects on renal function have been noted in regulatory reports.

Q: How quickly should the therapeutic effects of Mebutar Compuesto generally be noticed?

Official documents describe that the medication's mechanism of action involves rapidly disrupting the cell structure and energy supply of the target organisms. While this action begins quickly on the parasites, the time it takes for a person to notice relief from their symptoms will vary depending on the specific infection and individual response.

Q: What is the official guidance regarding discontinuing Mebutar Compuesto?

Official product information emphasizes the importance of using the medication for the full prescribed course to ensure complete elimination of the infection. The regimen should not be stopped early unless a healthcare professional has reviewed the situation.

Q: Does Mebutar Compuesto need to be taken with food, or can it be taken on an empty stomach?

Regulatory information commonly indicates that administration with food or immediately following a meal is advised. This condition is often noted to help minimize potential gastrointestinal side effects and may also improve the absorption of the active ingredients in the combination product.

Q: Is Mebutar Compuesto available over the counter, or does it require a prescription?

Mebutar Compuesto is generally classified by regulatory authorities as a prescription-only drug (often labeled 'Rx only') in most regions where it is sold. This classification means the medicine is not available over the counter and requires authorization from a licensed prescriber.

Q: Can Mebutar Compuesto affect a person's ability to sleep?

While specific insomnia is not always listed, official side effect reports mention Central Nervous System (CNS) reactions such as dizziness and headache. Regulatory documents also note occasional reports of drowsiness (somnolence), which can potentially interfere with a person's normal sleep schedule.

Q: Does Mebutar Compuesto cause changes in appetite or weight?

Yes, official adverse reaction reports sometimes list gastrointestinal disturbances that include anorexia, which is defined as a loss of appetite. These effects are generally manageable and are consistent with other side effects that can occur with anti-infective medications.

Q: What steps are officially advised if someone experiences a serious side effect?

Official product labeling contains statements that advise seeking medical attention immediately if severe symptoms are observed. This guidance applies to signs of serious reactions like blistering skin, severe rash, or new symptoms such as seizures or signs of infection.

Q: Does the time of day a person takes Mebutar Compuesto matter?

Regulatory information mandates that the medication be taken once daily. To support consistent drug concentrations in the bloodstream, the importance of maintaining evenly spaced times between doses is frequently highlighted in product information.

Q: What information is provided about what to do if a dose of Mebutar Compuesto is missed?

The product labeling contains specific instructions regarding what steps to take if a dose is missed. This information outlines the procedure for when a dose should be skipped to avoid taking a double amount. This procedural guidance is fully detailed in the 'How to Use Mebutar Compuesto' section of the official information.

Q: Is Mebutar Compuesto considered a controlled substance in any region?

No, official regulatory documents, such as the DEA Schedule in the US, indicate that the active ingredients in Mebutar Compuesto are not listed as controlled substances. This means the medication is not subject to the special restrictions applied to drugs with a high risk of abuse or dependence.

Advertisements

How should Mebutar Compuesto be stored and disposed of?

How to Store and Dispose of Mebutar Compuesto?

This medication must be stored according to regulatory requirements to maintain product quality. The official storage condition is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C.

Storage Constraints and Handling

  • Protection: The product must be kept from freezing and protected from excessive moisture and light.
  • Container: Store the medicine in the original container, ensuring it is tightly closed.
  • Child Safety: It is mandatory to keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be disposed of via a drug take-back program or an authorized collection point. If these options are unavailable, the medication may be mixed with an undesirable substance (such as dirt) and placed in a sealed container for disposal in household trash, according to general regulatory guidance. The medicine must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mebutar Compuesto found in:

A-Z Index: